Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From (For) Operating Activities
Net income (loss)	$ (68.9)	$ (162.6)	$ 146.1
Adjustments to derive cash flows:
Depreciation and amortization	312.2	384.8	396.5
Loss (Gain) on sale of business	(47.5)	20.9	(71.7)
Share-based compensation	60.1	58.5	52.2
Impairment charges	173.1	346.8	184.5
Change in financial assets	0.0	96.4	(22.1)
Loss on extinguishment of debt	0.0	20.0	0.2
Restructuring charges	16.9	3.5	26.3
Deferred income taxes	9.4	(54.5)	(43.9)
Amortization of debt premium	(3.8)	(2.4)	(4.4)
Other non-cash adjustments, net	0.2	(6.0)	37.6
Subtotal	451.7	705.4	701.3
Increase (decrease) in cash due to:
Accounts receivable	(159.7)	168.9	(140.7)
Inventories	(2.4)	(170.6)	(67.0)
Accounts payable	(7.9)	(2.7)	17.0
Payroll and related taxes	(53.0)	10.8	(3.7)
Accrued customer programs	1.4	(43.3)	(48.6)
Accrued liabilities	(21.4)	(23.1)	(23.2)
Accrued income taxes	(47.7)	(7.0)	(74.5)
Other, net	(4.7)	(2.2)	27.2
Subtotal	(295.4)	(69.2)	(313.5)
Net cash from (for) operating activities	156.3	636.2	387.8
Cash Flows From (For) Investing Activities
Proceeds from royalty rights	3.8	4.1	2.9
Acquisitions of businesses, net of cash acquired	0.0	(168.5)	(747.7)
Asset acquisitions	(70.6)	(35.2)	(149.1)
Purchase of equity method investment	0.0	(15.0)	0.0
Proceeds from the Royalty Pharma contingent milestone	0.0	0.0	250.0
Additions to property, plant and equipment	(152.1)	(170.4)	(137.7)
Net proceeds from sale of businesses	1,491.9	187.8	182.5
Other investing, net	2.8	9.4	3.0
Net cash from (for) investing activities	1,275.8	(187.8)	(596.1)
Cash Flows From (For) Financing Activities
Borrowings (repayments) of revolving credit agreements and other financing, net	(30.6)	(3.9)	0.5
Issuances of long-term debt	0.0	743.8	600.0
Payments on long-term debt	0.0	(590.0)	(476.0)
Premiums on early debt retirement	0.0	(19.0)	0.0
Deferred financing fees	0.0	(6.7)	(1.0)
Issuance of ordinary shares	0.0	0.0	0.9
Repurchase of ordinary shares	0.0	(164.2)	0.0
Cash dividends	(129.6)	(123.9)	(112.4)
Other financing, net	(18.5)	(17.2)	(10.2)
Net cash from (for) financing activities	(178.7)	(181.1)	1.8
Effect of exchange rate changes on cash and cash equivalents	(15.6)	19.9	9.7
Net increase (decrease) in cash and cash equivalents	1,237.8	287.2	(196.8)
Cash and cash equivalents of continuing operations, beginning of period	631.5	344.5	541.9
Cash and cash equivalents held for sale, beginning of period	10.0	9.8	9.2
Less cash and cash equivalents held for sale, end of period	(14.4)	(10.0)	(9.8)
Cash and cash equivalents of continuing operations, end of period	1,864.9	631.5	344.5
Cash paid/received during the year for:
Interest paid	133.0	145.8	136.8
Interest received	8.0	12.1	15.1
Income taxes paid	448.0	81.2	136.2
Income taxes refunded	$ 17.1	$ 38.3	$ 28.0